公开(公告)号：US20070073178A1

公开(公告)日：2007-03-29

申请号：US11522565

申请日：2006-09-18

Applicant: Ray Browning ,  Christopher Hall ,  Matthew Banet

Inventor： Ray Browning ,  Christopher Hall ,  Matthew Banet

IPC: A61B5/04

CPC classification number: A61B5/002 ,  A61B5/0022 ,  A61B5/024 ,  A61B5/11 ,  G16H40/67

Abstract: The invention provides a monitoring device that features: 1) a cardiac sensor component with at least one light-emitting diode and a photodetector; 2) a pedometer component with at least one motion-sensing component (e.g., an accelerometer); and 3) a wireless component with a wireless interface that communicates with an external weight scale. The device also features a microprocessor in electrical communication with the cardiac sensor, pedometer, and wireless components and configured to analyze: 1) a signal from the cardiac sensor component to generate heart rate information; 2) a signal from the pedometer component to generate exercise information; 3) heart rate and exercise information to generate calorie information; and 4) a signal from the external weight scale to calculate weight information (e.g., weight and percent body fat).

Abstract translation: 本发明提供了一种监测装置，其特征在于：1）具有至少一个发光二极管和光电检测器的心脏传感器部件; 2）具有至少一个运动感测部件（例如，加速度计）的计步器部件; 以及3）具有与外部重量秤通信的无线接口的无线部件。 该装置还具有与心脏传感器，计步器和无线部件电通信的微处理器，并且被配置为分析：1）来自心脏传感器部件的信号以产生心率信息; 2）来自计步器组件的信号以产生运动信息; 3）心率和运动信息产生卡路里信息; 和4）来自外部重量级的信号以计算重量信息（例如体重和身体脂肪百分比）。

公开(公告)号：US20040043496A1

公开(公告)日：2004-03-04

申请号：US10463664

申请日：2003-06-16

Applicant: Berkeley HeartLab, Inc.

Inventor： H. Robert Superko

IPC: G01N033/92

CPC classification number: G01N33/92 ,  G01N2800/52

Abstract: The invention provides a method for identifying patients who will require multiple invasive cardiac procedures comprising measuring elevated LDL IVb levels in patients who have had or will have invasive heart surgery.

Abstract translation: 本发明提供了一种用于鉴定需要多次侵入性心脏手术的患者的方法，包括测量已经或将要进行侵入性心脏手术的患者的升高的LDL IVb水平。

公开(公告)号：US20250027960A1

公开(公告)日：2025-01-23

申请号：US18829111

申请日：2024-09-09

Applicant: CLEVELAND HEARTLAB, INC.

Inventor： Timothy Collier ,  Cory Bystrom ,  Angela Higgins

IPC: G01N33/92 ,  C07K14/775 ,  G01N1/34

Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.

公开(公告)号：US07842506B2

公开(公告)日：2010-11-30

申请号：US11702961

申请日：2007-02-06

Applicant: Christopher Hall ,  Vance Lanier, Jr. ,  David T. Shewmake

Inventor： Christopher Hall ,  Vance Lanier, Jr. ,  David T. Shewmake

IPC: G01N33/92

CPC classification number: C12Q1/6883 ,  C12Q2600/156 ,  G01N33/92 ,  G06F19/00 ,  G06F19/18 ,  G06Q50/24

Abstract: The invention provides a system for monitoring a patient that includes: 1) a blood test that measures an Apo E genotype or a derivative thereof from the patient to generate Apo B information; 2) a database that receives and stores the patient's Apo E information; and 3) an Internet-based system connected to the database and configured to process the Apo E information with an algorithm that, in response, generates a diet and treatment plan for the patient.

Abstract translation: 本发明提供一种用于监测患者的系统，其包括：1）测量来自患者的Apo E基因型或其衍生物的血液检测以产生Apo B信息; 2）接收并存储患者Apo E信息的数据库; 以及3）基于因特网的系统，其连接到所述数据库并被配置为利用所述算法处理所述Apo E信息，所述算法作为响应，为所述患者产生饮食和治疗计划。

公开(公告)号：US20090188796A1

公开(公告)日：2009-07-30

申请号：US12197694

申请日：2008-08-25

Applicant: David Shewmake ,  Frank Ruderman ,  Christopher Boggess ,  Faith Clendenen

Inventor： David Shewmake ,  Frank Ruderman ,  Christopher Boggess ,  Faith Clendenen

IPC: G01N27/447

CPC classification number: G01N33/92 ,  C25B1/285 ,  G01N2800/32 ,  G01N2800/52 ,  Y10T436/104165

Abstract: The invention provides a data base of LDL, I, IIa, IIb, IIIa, IIb, IVa, IVb and HDL2a, HDL2b, HDL 3a, HDL 3b and HDL 3c together with patient data such as HDL-C, LDL-C, Apo A, ApoB, Lp(a) and patient personal data useful for treatment, diagnosing, and monitoring cardiovascular disease. The data base contains the LDL and HDL subfraction data in quantitative mg/dl values and permits deriving relationship amongst the LDL and HDL values and cardiovascular disease. Quantitative data permits more effective treatment and monitoring of cardiovascular disease. For example, quantitative differences in LDL and HDL subclass levels can determine the need for more or less aggressive treatment. The data base which includes patient events, procedures, interventions which is correlated to LDL and HDl quantitative subclass data permits development of personalized patient treatment plans and monitoring the effectiveness of such treatment. Thus, LDL and HDL quantitative subfraction data can be used to more effectively treat and monitor cardiovascular disease.The invention, for example, provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels. LDL III a & b and HDL 2b are preferred subclasses.

Abstract translation: 本发明提供LDL，I，IIa，IIb，IIIa，IIb，IVa，IVb和HDL2a，HDL2b，HDL 3a，HDL 3b和HDL 3c的数据库以及患者数据如HDL-C，LDL-C，Apo A，ApoB，Lp（a）和患者个人资料可用于治疗，诊断和监测心血管疾病。 数据库包含定量mg / dl值中的LDL和HDL次级分数据，并允许LDL和HDL值与心血管疾病之间的关系。 定量数据可以更有效地治疗和监测心血管疾病。 例如，LDL和HDL亚类水平的定量差异可以确定对或多或少积极治疗的需要。 包括与LDL和HDI定量亚类数据相关的患者事件，程序，干预措施的数据库允许开发个性化的患者治疗计划并监测此类治疗的有效性。 因此，LDL和HDL定量分数据可用于更有效地治疗和监测心血管疾病。 例如，本发明提供了一种用于鉴定需要治疗心血管疾病的正常NCEP脂质水平的患者的方法，包括测量一种或多种LDL或HDL颗粒亚类水平并鉴定异常的LDL或HDL亚类水平。 LDL III a＆b和HDL 2b是优选的亚类。

公开(公告)号：US07416895B2

公开(公告)日：2008-08-26

申请号：US10412838

申请日：2003-04-12

Applicant: David Shewmake ,  Frank Ruderman ,  Christopher Boggess ,  Faith Clendenen

Inventor： David Shewmake ,  Frank Ruderman ,  Christopher Boggess ,  Faith Clendenen

IPC: G01N33/92

CPC classification number: G01N33/92 ,  C25B1/285 ,  G01N2800/32 ,  G01N2800/52 ,  Y10T436/104165

Abstract: This invention is directed to a data base which contains data for HDL2b, LDL IIIa & LDL IIIb and LDL IVb subclasses all in mg/Dl and which is correlated to cardiovascular disease.

Abstract translation: 本发明涉及一种数据库，其中包含HDL2b，LDL IIIa和LDL IIIb和LDL IVb亚类的数据，全部以mg / dl表示，并与心血管疾病相关。

公开(公告)号：US20070224619A1

公开(公告)日：2007-09-27

申请号：US11702961

申请日：2007-02-06

Applicant: Matthew Banet ,  Randon Schultz ,  Marshal Dhillon ,  Adam Fleming ,  Henk Visser ,  Christopher Hall ,  Vance Lanier

Inventor： Matthew Banet ,  Randon Schultz ,  Marshal Dhillon ,  Adam Fleming ,  Henk Visser ,  Christopher Hall ,  Vance Lanier

IPC: C12Q1/68 ,  C12Q1/60

CPC classification number: C12Q1/6883 ,  C12Q2600/156 ,  G01N33/92 ,  G06F19/00 ,  G06F19/18 ,  G06Q50/24

Abstract: The invention provides a system for monitoring a patient that includes: 1) a blood test that measures an Apo E genotype or a derivative thereof from the patient to generate Apo B information; 2) a database that receives and stores the patient's Apo E information; and 3) an Internet-based system connected to the database and configured to process the Apo E information with an algorithm that, in response, generates a diet and treatment plan for the patient.

Abstract translation: 本发明提供一种用于监测患者的系统，其包括：1）测量来自患者的Apo E基因型或其衍生物的血液检测以产生Apo B信息; 2）接收并存储患者Apo E信息的数据库; 以及3）基于因特网的系统，其连接到所述数据库并被配置为利用所述算法处理所述Apo E信息，所述算法作为响应，为所述患者产生饮食和治疗计划。

公开(公告)号：US20070072302A1

公开(公告)日：2007-03-29

申请号：US11522591

申请日：2006-09-18

Applicant: Faith Clendenen ,  Christopher Boggess ,  Frank Ruderman

Inventor： Faith Clendenen ,  Christopher Boggess ,  Frank Ruderman

IPC: G01N33/92

CPC classification number: G01N33/92

Abstract: The invention provides a method (e.g., a computer algorithm) for calculating a number of particles in a LDL subfraction. The method features the steps of: 1) measuring an initial distribution of LDL particles (e.g., a relative mass distribution) from a blood sample; 2) processing the initial distribution of LDL particles with a mathematical model to determine a modified distribution of LDL particles (e.g., a relative particle distribution); 3) determining a total LDL particle number value from a blood sample; and 4) analyzing both the modified distribution of particles and the total LDL particle number value to calculate the particle number value in an LDL subfraction.

Abstract translation: 本发明提供了一种用于计算LDL子分数中的粒子数量的方法（例如，计算机算法）。 该方法的特征在于：1）测量来自血液样本的LDL颗粒的初始分布（例如相对质量分布）; 2）用数学模型处理LDL颗粒的初始分布，以确定LDL颗粒的修饰分布（例如，相对颗粒分布）; 3）从血液样品中确定总LDL颗粒数值; 和4）分析改性粒子分布和总LDL粒子数值，以计算LDL亚分数中的粒子数值。

公开(公告)号：US20060161065A1

公开(公告)日：2006-07-20

申请号：US11335841

申请日：2006-01-18

Applicant: Jonathan Elion

Inventor： Jonathan Elion

IPC: A61B5/04

CPC classification number: A61B5/0452 ,  A61B5/117 ,  G06K9/00536 ,  G06K2009/00939

Abstract: An ECG management system provides a computer-assisted Quality Assurance step in an ECG management system. This step is preferably performed prior to releasing ECGs to the cardiologists for interpretation placement in the patient's permanent records. It involve comparing the ECG wave data to previously collected ECG data for the same and/or different named patients to enable error correction and/or proper patient naming.

Abstract translation: ECG管理系统在ECG管理系统中提供计算机辅助的质量保证步骤。 该步骤优选在将心电图释放到患者的永久性记录中之前进行心脏病学家的解释放置。 它涉及将ECG波数据与先前收集的相同和/或不同命名患者的ECG数据进行比较，以使得能够进行纠错和/或适当的患者命名。

公开(公告)号：US11237167B2

公开(公告)日：2022-02-01

申请号：US15874078

申请日：2018-01-18

Applicant: Cleveland HeartLab, Inc.

Inventor： Celalettin Topbas ,  Cory Bystrom

IPC: G01N33/573 ,  G01N1/28

Abstract: Provided herein are methods, systems, and compositions for Lp-PLA2 detection assays that employ amounts of detergent to liberate all or nearly all of the Lp-PLA2 molecules from associated lipoprotein particles. In this regard, the true Lp-PLA2 concentration can be detected in a sample, which correlates better with known Lp-PLA2 activity assays.